JP Morgan Chase’s Tourmaline Bio TRML Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-14,291
| Closed | -$684K | – | 7786 |
|
|
2025
Q3 | $684K | Sell |
14,291
-1,308
| -8% | -$36.3K | ﹤0.01% | 4842 |
|
|
2025
Q2 | $249K | Sell |
15,599
-24,101
| -61% | -$390K | ﹤0.01% | 5131 |
|
|
2025
Q1 | $604K | Buy |
39,700
+24,995
| +170% | +$401K | ﹤0.01% | 4660 |
|
|
2024
Q4 | $298K | Sell |
14,705
-99
| -0.7% | -$2.49K | ﹤0.01% | 5298 |
|
|
2024
Q3 | $381K | Buy |
14,804
+2,100
| +17% | +$35.1K | ﹤0.01% | 5086 |
|
|
2024
Q2 | $163K | Buy |
12,704
+6,574
| +107% | +$106K | ﹤0.01% | 5262 |
|
|
2024
Q1 | $140K | Buy |
6,130
+1,622
| +36% | +$57.2K | ﹤0.01% | 5527 |
|
|
2023
Q4 | $118K | Sell |
4,508
-34,305
| -88% | -$687K | ﹤0.01% | 5655 |
|
|
2023
Q3 | $1.09M | Sell |
38,813
-6,490
| -14% | -$190K | ﹤0.01% | 4002 |
|
|
2023
Q2 | $1.38M | Buy |
45,303
+43,469
| +2,370% | +$1.11M | ﹤0.01% | 3814 |
|
|
2023
Q1 | $34K | Buy |
1,834
+461
| +34% | +$7.6K | ﹤0.01% | 5836 |
|
|
2022
Q4 | $14K | Sell |
1,373
-138
| -9% | -$2.22K | ﹤0.01% | 5975 |
|
|
2022
Q3 | $40K | Buy |
1,511
+142
| +10% | +$5.17K | ﹤0.01% | 5618 |
|
|
2022
Q2 | $62K | Sell |
1,369
-114
| -8% | -$8.99K | ﹤0.01% | 5597 |
|
|
2022
Q1 | $146K | Buy |
1,483
+309
| +26% | +$28.9K | ﹤0.01% | 5341 |
|
|
2021
Q4 | $179K | Buy |
1,174
+566
| +93% | +$83.7K | ﹤0.01% | 5420 |
|
|
2021
Q3 | $82K | Sell |
608
-705
| -54% | -$96.5K | ﹤0.01% | 5671 |
|
|
2021
Q2 | $193K | Buy |
+1,313
| New | +$201K | ﹤0.01% | 5266 |
|
JP Morgan Chase's TRML Position: Q4 2025 in Review
JP Morgan Chase sold out of Tourmaline Bio (TRML) in Q4 2025, closing a stake of 14,291 shares — an estimated $684K sold.
JP Morgan Chase first reported a position in TRML in Q2 2021 and held it in 18 quarters. The position peaked at $1.38M in Q2 2023. 0 funds tracked by Wall St. Rank hold TRML as of Q4 2025.
- JP Morgan Chase reported no remaining Tourmaline Bio position as of Q4 2025 after selling out during the quarter.
- JP Morgan Chase sold 14,291 Tourmaline Bio shares in Q4 2025, an estimated $684K.
- JP Morgan Chase first reported a position in Tourmaline Bio in Q2 2021 and held it in 18 quarters.
- JP Morgan Chase's Tourmaline Bio position peaked at $1.38M in Q2 2023.
- 0 funds tracked by Wall St. Rank held Tourmaline Bio as of Q4 2025.
Based on JP Morgan Chase's 13F filing for Q4 2025, filed 11 Feb 2026.